Brief: Entrada Therapeutics Inc - Approves Strategic Plan Focusing On DMD Programs - SEC Filing
29/04/2025 22:44
April 29 (Reuters) - Entrada Therapeutics Inc TRDA.O: ENTRADA THERAPEUTICS INC - APPROVES STRATEGIC PLAN FOCUSING ON DMD PROGRAMS - SEC FILING ENTRADA THERAPEUTICS INC - TO REDUCE WORKFORCE BY APPROXIMATELY 20% UNDER NEW PLAN - SEC FILING ENTRADA THERAPEUTICS INC - EXPECTS CASH RUNWAY TO EXTEND INTO Q2 2027 - SEC FILING Source text: [ID:n0001104659-25-041204] Further company coverage: TRDA.O ((Reuters.Briefs@thomsonreuters.com))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview